



NDA 21003/S-017
NDA 21004/S-017

SUPPLEMENT APPROVAL

GlaxoSmithKline, LLC
Attention: Leslie Driver, Pharm D.,
Director, Global Regulatory Affairs
Five Moore Drive, P.O. Box 13398, Mailstop 5.5B
Research Triangle Park, NC 27709

Dear Dr. Driver:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received March 28, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for EPIVIR-HBV[®] (lamivudine) 100 mg tablets and 5 mg per mL oral solution.

These Prior Approval supplemental new drug applications provide for the following changes to the labeling:

- To update the DRUG INTERACTIONS, CLINICAL PHARMACOLOGY, and PATIENT COUNSELING INFORMATION sections, to include drug interaction information with sorbitol-containing solutions based on data from a pharmacokinetic trial conducted in healthy adult subjects.
- To update CLINICAL PHARMACOLOGY, Pharmacokinetics section with two new subsections; Effects of Lamivudine on the Pharmacokinetics of Other Agents and Effects of Other Agents on the Pharmacokinetics of Lamivudine, and to include data on in-vitro transporters.
- To align the label with the current approved EPIVIR-HIV label.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. The applications are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For

more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Victoria Tyson, Regulatory Project Manager, at (301) 796-0827.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.

Director

Division of Antiviral Products

Office of Antimicrobial Products

Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

POONAM MISHRA

09/27/2017

on behalf of Debra Birnkrant, MD